Valamehr Bahram's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Sep 14, 2021
- Accession no.
- 0001209191-21-055867
- Filed
- Sep 14, 2021
- Trade date
- Sep 13, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.66M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Valamehr BahramCIK 0001748177 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2021 | Common Stock | MOption exerciseAcquired | +25,000 | $2.73 | +$68,250 | 120,740 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −15,809 | $65.94F2 | −$1,042,445.46 | 104,931 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −8,391 | $66.84F3 | −$560,854.44 | 96,540 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −800 | $67.46F4 | −$53,968 | 95,740 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2021 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 86,156 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $65.40 to $66.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $66.40 to $67.38 per share.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price of the shares sold from $67.40 to $67.54 per share.
Referenced by the price of 1 transaction in Table I.